NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nurix Therapeutics (NRIX) is a good buy for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a constructive technical setup, strong bullish analyst support, and favorable options sentiment. However, it is still an early-stage biotech name, so the position should be sized as a long-term growth/speculative allocation rather than a core low-risk holding. Based on the data provided, I would rate it a buy right now.
NRIX is in a bullish trend: SMA_5 is above SMA_20 and SMA_200, and the MACD histogram is positive at 0.691, though it is contracting, which suggests momentum is still positive but not accelerating. RSI_6 is 88.56, which is overbought, so the stock may be extended short term. Price at 23.60 is near resistance at 24.163, with the next upside level at 26.034 and pivot support at 21.134. Overall, the technical trend is bullish, but the current entry is somewhat stretched.
["Oppenheimer initiated coverage with an Outperform rating and $28 target, highlighting Bexdeg and STAT6 degrader as promising programs.", "Baird raised its price target to $33 from $26 and kept an Outperform rating, citing partnership with Roche and continued clinical performance.", "Bullish moving average structure and positive MACD support the current uptrend.", "Options flow is strongly call-biased, indicating bullish trader sentiment.", "Stock pattern data suggests a positive probability bias over the next day, week, and month."]
["RSI_6 at 88.56 indicates the stock is overbought and could pause after the recent run.", "Wells Fargo downgraded the stock on 2026-06-08, showing not all analysts are uniformly bullish.", "Post-market action was negative at -1.54%, suggesting some near-term cooling.", "No recent news catalysts in the past week, so the move is not being reinforced by fresh headlines.", "Financial snapshot data was unavailable, limiting confirmation of latest operating momentum."]
Financial data is limited because the latest quarter snapshot was unavailable. Based on the provided analyst notes, the most recent quarter included a wider GAAP net loss than expected, driven mainly by lower-than-expected collaborative revenue. At the same time, clinical development for bexobrutideg continues to advance, including ongoing enrollment in the Phase 2 DAYBreak CLL-201 trial and expected progress toward the Phase 3 DAYBreak CLL-306 trial in mid-2026. Since the latest quarter season was not provided, I cannot give a precise quarter-season assessment.
Analyst sentiment is clearly positive overall. Recent actions include Oppenheimer initiating Outperform with a $28 target and Baird raising its target to $33 from $26 while maintaining Outperform. Earlier, Wells Fargo lowered its target to $28 and had a more cautious view, and Stifel reduced its target to $34 after a wider-than-expected GAAP loss. Wall Street’s pros view is that Nurix has valuable pipeline assets, especially Bexdeg and STAT6 degrader, plus upside from Roche partnership and clinical progress. The cons view centers on losses, dependence on clinical execution, and the lack of near-term profitability.
